Cargando…
Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome
This study investigated the effects of long-term treatment with rifaximin and the probiotic VSL#3 on uro-genital and gastrointestinal symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) plus diarrhoea-predominant irritable bowel syndrome (D-IBS) compared with patient...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707680/ https://www.ncbi.nlm.nih.gov/pubmed/29099760 http://dx.doi.org/10.3390/nu9111208 |
_version_ | 1783282485355872256 |
---|---|
author | Vicari, Enzo Salemi, Michele Sidoti, Giuseppe Malaguarnera, Mariano Castiglione, Roberto |
author_facet | Vicari, Enzo Salemi, Michele Sidoti, Giuseppe Malaguarnera, Mariano Castiglione, Roberto |
author_sort | Vicari, Enzo |
collection | PubMed |
description | This study investigated the effects of long-term treatment with rifaximin and the probiotic VSL#3 on uro-genital and gastrointestinal symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) plus diarrhoea-predominant irritable bowel syndrome (D-IBS) compared with patients with D-IBS alone. Eighty-five patients with CP/CPPS (45 with subtype IIIa and 40 with IIIb) plus D-IBS according to the Rome III criteria and an aged-matched control-group of patients with D-IBS alone (n = 75) received rifaximin and VSL#3. The primary endpoints were the response rates of IBS and CP/CPPS symptoms, assessed respectively through Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) and The National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and performed at the start of therapy (V0) and three months after (V3). In IIIa prostatitis patients, the total NIH-CPSI scores significantly (p < 0.05) decreased from a baseline mean value of 21.2 to 14.5 at V3 , as did all subscales, and in the IIIb the total NIH-CPSI score also significantly decreased (from 17.4 to 15.1). Patients with IBS alone showed no significant differences in NIH-CPSI score. At V3, significantly greater improvement in the IBS-SSS and responder rate were found in IIIa patients. Our results were explained through a better individual response at V3 in IIIa prostatitis of urinary and gastrointestinal symptoms, while mean leukocyte counts on expressed prostate secretion (EPS) after prostate massage significantly lowered only in IIIa cases. |
format | Online Article Text |
id | pubmed-5707680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-57076802017-12-05 Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome Vicari, Enzo Salemi, Michele Sidoti, Giuseppe Malaguarnera, Mariano Castiglione, Roberto Nutrients Article This study investigated the effects of long-term treatment with rifaximin and the probiotic VSL#3 on uro-genital and gastrointestinal symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) plus diarrhoea-predominant irritable bowel syndrome (D-IBS) compared with patients with D-IBS alone. Eighty-five patients with CP/CPPS (45 with subtype IIIa and 40 with IIIb) plus D-IBS according to the Rome III criteria and an aged-matched control-group of patients with D-IBS alone (n = 75) received rifaximin and VSL#3. The primary endpoints were the response rates of IBS and CP/CPPS symptoms, assessed respectively through Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) and The National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and performed at the start of therapy (V0) and three months after (V3). In IIIa prostatitis patients, the total NIH-CPSI scores significantly (p < 0.05) decreased from a baseline mean value of 21.2 to 14.5 at V3 , as did all subscales, and in the IIIb the total NIH-CPSI score also significantly decreased (from 17.4 to 15.1). Patients with IBS alone showed no significant differences in NIH-CPSI score. At V3, significantly greater improvement in the IBS-SSS and responder rate were found in IIIa patients. Our results were explained through a better individual response at V3 in IIIa prostatitis of urinary and gastrointestinal symptoms, while mean leukocyte counts on expressed prostate secretion (EPS) after prostate massage significantly lowered only in IIIa cases. MDPI 2017-11-03 /pmc/articles/PMC5707680/ /pubmed/29099760 http://dx.doi.org/10.3390/nu9111208 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vicari, Enzo Salemi, Michele Sidoti, Giuseppe Malaguarnera, Mariano Castiglione, Roberto Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome |
title | Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome |
title_full | Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome |
title_fullStr | Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome |
title_full_unstemmed | Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome |
title_short | Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome |
title_sort | symptom severity following rifaximin and the probiotic vsl#3 in patients with chronic pelvic pain syndrome (due to inflammatory prostatitis) plus irritable bowel syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707680/ https://www.ncbi.nlm.nih.gov/pubmed/29099760 http://dx.doi.org/10.3390/nu9111208 |
work_keys_str_mv | AT vicarienzo symptomseverityfollowingrifaximinandtheprobioticvsl3inpatientswithchronicpelvicpainsyndromeduetoinflammatoryprostatitisplusirritablebowelsyndrome AT salemimichele symptomseverityfollowingrifaximinandtheprobioticvsl3inpatientswithchronicpelvicpainsyndromeduetoinflammatoryprostatitisplusirritablebowelsyndrome AT sidotigiuseppe symptomseverityfollowingrifaximinandtheprobioticvsl3inpatientswithchronicpelvicpainsyndromeduetoinflammatoryprostatitisplusirritablebowelsyndrome AT malaguarneramariano symptomseverityfollowingrifaximinandtheprobioticvsl3inpatientswithchronicpelvicpainsyndromeduetoinflammatoryprostatitisplusirritablebowelsyndrome AT castiglioneroberto symptomseverityfollowingrifaximinandtheprobioticvsl3inpatientswithchronicpelvicpainsyndromeduetoinflammatoryprostatitisplusirritablebowelsyndrome |